<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01246011</url>
  </required_header>
  <id_info>
    <org_study_id>2010P001386</org_study_id>
    <nct_id>NCT01246011</nct_id>
  </id_info>
  <brief_title>Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion</brief_title>
  <official_title>Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heparin/Platelet Factor 4 (PF4) antibody testing will be performed in subjects who have just
      undergone coronary artery bypass grafting (CABG) surgery. 30 subjects with a positive
      antibody result and no signs or symptoms of Heparin Induced Thrombocytopenia (HIT) will be
      randomized to receive argatroban and warfarin. 30 subjects with a positive antibody result
      and no signs or symptoms of HIT will be randomized to receive no treatment. 30 subjects with
      a negative antibody result will also be followed in the study. All subjects will have a
      cardiac CT scan at about 30 days post surgery to measure the patency of their coronary artery
      bypass vein grafts. This study will evaluate if treating patients who have heparin PF4
      antibodies post-CABG with argatroban and warfarin has any effect on the short-term patency of
      coronary artery bypass vein grafts.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, single center study. Patients scheduled for CABG will be
      screened and enrolled. Subjects positive for heparin/PF4 antibody within 24 h after CABG and
      without clinical suspicion of HIT will be randomized into one of two groups. An additional 30
      patients with negative antibody titers will serve as a control group.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrollment was too slow.
  </why_stopped>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary Artery Bypass Vein Graft Patency</measure>
    <time_frame>Approximately 30 Days post CABG</time_frame>
    <description>Vein graft patency as measured by computed tomography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Bleeding Events.</measure>
    <time_frame>At 2weeks post CABG</time_frame>
    <description>Intracranial bleed or any clinically overt sign of hemorrhage that is associated with a fall in hemoglobin &gt; 5 g/dL.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Coronary Artery Bypass Graft Surgery</condition>
  <condition>Presence of Heparin/Platelet Factor 4 Antibody</condition>
  <arm_group>
    <arm_group_label>Heparin PF4 antibody positive -Drug (argatroban and warfarin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Post-CABG heparin PF4 antibody positive with no signs or symptoms of HIT randomized to receive argatroban and warfarin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heparin PF4 antibody positive no drug</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Post-CABG heparin PF4 antibody positive with no signs or symptoms of HIT randomized to receive no medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heparin PF4 antibody negative</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Post-CABG heparin PF4 antibody negative with no signs or symptoms of HIT randomized to receive no medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Argatroban and warfarin</intervention_name>
    <description>Subjects with the presence of heparin PF4 antibodies without signs or symptoms of HIT post CABG will be randomized to receive argatroban and warfarin or no drug for one month.</description>
    <arm_group_label>Heparin PF4 antibody positive -Drug (argatroban and warfarin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients scheduled for CABG (males or non-pregnant females)

          2. &gt; 18 years old with at least one vein graft planned

          3. Able to provide written informed consent

        Exclusion Criteria:

          1. Patients who, in the investigator's or attending surgeon's opinion, are unsuitable for
             anticoagulation due to their clinical status

          2. Documented history of allergy to iodinated contrast media, warfarin, or argatroban

          3. Chronic renal impairment with CrCl&lt;60 ml/min

          4. Recent bleeding episode

          5. Congestive Heart Failure (EF&lt; 30%)

          6. Bleeding diathesis or known thrombophilic disorder

          7. Atrial fibrillation or other condition requiring anticoagulation at the time of
             enrollment

          8. Documented history of heparin induced thrombocytopenia

          9. Clinical suspicion of HIT at the time of randomization, defined as 50% decrease in
             Platelet count from last heparin exposure or Platelet count &lt;100,000/ml

         10. Hepatic dysfunction (defined as LFTs &gt; 3 times the upper limit of normal)

         11. Patients with a history of bleeding complications post-CABG

         12. Hemorrhagic stroke

         13. Gastrointestinal bleeding

         14. Requirement for fresh frozen plasma

         15. Recent central nervous system or ophthalmic surgery

         16. Aneurysm

         17. History of psychosis or senility

         18. Malignant hypertension

         19. Clinically significant pericarditis or pericardial effusion

         20. Bacterial endocarditis

         21. Hematocrit &lt; 24%

         22. Valve replacement or repair at time of CABG

         23. Subjects with signs or symptoms of possible Transient Ischemic Attack or stroke
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ik-Kyung Jang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2010</study_first_submitted>
  <study_first_submitted_qc>November 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2010</study_first_posted>
  <results_first_submitted>January 3, 2012</results_first_submitted>
  <results_first_submitted_qc>March 9, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 12, 2012</results_first_posted>
  <last_update_submitted>October 16, 2017</last_update_submitted>
  <last_update_submitted_qc>October 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Ik-Kyung Jang, MD, PhD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Argatroban</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Platelet Factor 4</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study began enrolling in January 2011 and screening ended in July 2011, after it was decided that enrollment was too slow and that the study should be terminated.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Heparin PF4 Antibody Positive -Drug (Argatroban and Warfarin)</title>
          <description>Post-CABG heparin PF4 antibody positive with no signs or symptoms of HIT randomized to receive argatroban and warfarin</description>
        </group>
        <group group_id="P2">
          <title>Heparin PF4 Antibody Positive no Drug</title>
          <description>Post-CABG heparin PF4 antibody positive with no signs or symptoms of HIT randomized to receive no medication</description>
        </group>
        <group group_id="P3">
          <title>Heparin PF4 Antibody Negative</title>
          <description>Post-CABG heparin PF4 antibody negative with no signs or symptoms of HIT randomized to receive no medication</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>If needed warfarin clinically, withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Heparin PF4 Antibody Positive -Drug (Argatroban and Warfarin)</title>
          <description>Post-CABG heparin PF4 antibody positive with no signs or symptoms of HIT randomized to receive argatroban and warfarin</description>
        </group>
        <group group_id="B2">
          <title>Heparin PF4 Antibody Positive no Drug</title>
          <description>Post-CABG heparin PF4 antibody positive with no signs or symptoms of HIT randomized to receive no medication</description>
        </group>
        <group group_id="B3">
          <title>Heparin PF4 Antibody Negative</title>
          <description>Post-CABG heparin PF4 antibody negative with no signs or symptoms of HIT randomized to receive no medication</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="61.9" spread="11.3"/>
                    <measurement group_id="B4" value="61.9" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Coronary Artery Bypass Vein Graft Patency</title>
        <description>Vein graft patency as measured by computed tomography</description>
        <time_frame>Approximately 30 Days post CABG</time_frame>
        <population>No analysis will be done due to early study termination</population>
        <group_list>
          <group group_id="O1">
            <title>Heparin PF4 Antibody Positive -Drug (Argatroban and Warfarin)</title>
            <description>Post-CABG heparin PF4 antibody positive with no signs or symptoms of HIT randomized to receive argatroban and warfarin</description>
          </group>
          <group group_id="O2">
            <title>Heparin PF4 Antibody Positive no Drug</title>
            <description>Post-CABG heparin PF4 antibody positive with no signs or symptoms of HIT randomized to receive no medication</description>
          </group>
          <group group_id="O3">
            <title>Heparin PF4 Antibody Negative</title>
            <description>Post-CABG heparin PF4 antibody negative with no signs or symptoms of HIT randomized to receive no medication</description>
          </group>
        </group_list>
        <measure>
          <title>Coronary Artery Bypass Vein Graft Patency</title>
          <description>Vein graft patency as measured by computed tomography</description>
          <population>No analysis will be done due to early study termination</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Bleeding Events.</title>
        <description>Intracranial bleed or any clinically overt sign of hemorrhage that is associated with a fall in hemoglobin &gt; 5 g/dL.</description>
        <time_frame>At 2weeks post CABG</time_frame>
        <population>No analysis will be done due to early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Heparin PF4 Antibody Positive -Drug (Argatroban and Warfarin)</title>
            <description>Post-CABG heparin PF4 antibody positive with no signs or symptoms of HIT randomized to receive argatroban and warfarin
Argatroban and warfarin: Subjects with the presence of heparin PF4 antibodies without signs or symptoms of HIT post CABG will be randomized to receive argatroban and warfarin or no drug for one month.</description>
          </group>
          <group group_id="O2">
            <title>Heparin PF4 Antibody Positive no Drug</title>
            <description>Post-CABG heparin PF4 antibody positive with no signs or symptoms of HIT randomized to receive no medication</description>
          </group>
          <group group_id="O3">
            <title>Heparin PF4 Antibody Negative</title>
            <description>Post-CABG heparin PF4 antibody negative with no signs or symptoms of HIT randomized to receive no medication</description>
          </group>
        </group_list>
        <measure>
          <title>Major Bleeding Events.</title>
          <description>Intracranial bleed or any clinically overt sign of hemorrhage that is associated with a fall in hemoglobin &gt; 5 g/dL.</description>
          <population>No analysis will be done due to early study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <desc>1 subject withdrew from the study prior to having a specimen drawn, so there were only 8 participants at risk</desc>
      <group_list>
        <group group_id="E1">
          <title>Heparin PF4 Antibody Positive -Drug (Argatroban and Warfarin)</title>
          <description>Post-CABG heparin PF4 antibody positive with no signs or symptoms of HIT randomized to receive argatroban and warfarin</description>
        </group>
        <group group_id="E2">
          <title>Heparin PF4 Antibody Positive no Drug</title>
          <description>Post-CABG heparin PF4 antibody positive with no signs or symptoms of HIT randomized to receive no medication</description>
        </group>
        <group group_id="E3">
          <title>Heparin PF4 Antibody Negative</title>
          <description>Post-CABG heparin PF4 antibody negative with no signs or symptoms of HIT randomized to receive no medication</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation after Coronary Artery Bypass Surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Bleeding during or immediately after Coronary Artery Bypass Surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension after Coronary Artery Bypass Graft Surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Low Hematocrit after Coronary Artery Bypass Graft Surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Post operative nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back spasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Parkinson's-like features</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Retention after Coronary Artery Bypass Surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was ended early due to slow enrollment and results will not be analyzed. The 4 subjects who completed the study were all in the same arm of the study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Anne Philip, Data Manager</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617 726 0423</phone>
      <email>alphilip@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

